Modern Clinical Medicine Research

Download PDF (231.1 KB) PP. 1 - 6 Pub. Date: April 13, 2017

DOI: 10.22606/mcmr.2017.11001

• Kazutoshi Fujita
  Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
• J. Kellogg Parsons
  Division of Urologic Oncology, Moores Comprehensive Cancer Center, University of California, San Diego and Division of Urology, San Diego Veterans Affairs Medical Center, La Jolla, CA, USA
• Charles M. Ewing
  The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
• George J Netto
  The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
• William B. Isaacs
  The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
• Christian P. Pavlovich^*
  The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Monocyte chemotactic protein-1 (MCP-1) is differentially expressed in benign prostatic
hyperplasia (BPH) and is a potential clinical biomarker for BPH. We collected urine post-digital rectal
examination (DRE) from 48 men who did not have a diagnosis of prostate cancer. We measured MCP-1
levels by enzyme-linked immunosorbent assay (ELISA) and compared them with prostate weight and
lower urinary tract symptoms (LUTS) as measured by the International Prostate Symptom Score
(I-PSS) utilizing correlation and regression analyses. In post-DRE urine, higher MCP-1 levels were
associated with increased I-PSS but not with prostate volume. MCP-1 levels in men with prostate
enlargement were significantly higher than those in men without enlargement. In multivariable
regression adjusting for age, prostate volume, and PSA,higher urinary MCP-1 was associated with
significantly higher I-PSS. Since MCP-1 is preferentially expressed in BPH tissue, these data suggest
that MCP-1 may be a novel biomarker for clinically significant BPH.

MCP-1, LUTS, urine marker, benign prostatic hyperplasia

[1] J. T. Wei, E. Calhoun, S. J. Jacobsen, “Urologic diseases in America project: benign prostatic hyperplasia.” Journal of Urology, vol. 173, no. 4, pp. 1256-1261, 2005.

[2] K. Fujita, C. M. Ewing, R.H. Getzenberg, J. K. Parsons, W. B. Isaacs, C. P. Pavlovich, “Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia”, Prostate, vol. 70, no. 5, pp. 473-481, 2010; 70.

[3] N. Mukaida, A. Harada, K. Matsushima, “Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions”. Cytokine & Growth Factor Reviews, vol. 9, no. 1, pp. 9-23, 1998.

[4] L. Mazzucchelli, P. Loetscher, A. Kappeler, M. Uguccioni, M. Baggiolini, J. A. Laissue et al. “Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma”. American Journal of Pathology, vol. 149, no. 2, pp. 501-509, 1996.

[5] J. K. Parsons, J. Bergstrom, J. Silberstein, E. Barrett-Connor. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology, vol. 72, no. 2, pp. 318-321, 2008.

[6] A. Chetcuti, S. Margan, S. Mann, P. Russell, D. Handelsman, J. Rogers et al. “Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array”. Prostate, vol. 47, no. 2, pp. 132-140, 2001.

[7] R. D. Loberg, L. L. Day, J. Harwood, C. Ying, L. N. St John, R. Giles et al. “CCL2 is a potent regulator of prostate cancer cell migration and proliferation”. Neoplasia, vol. 8, no. 7, pp. 578-586, 2006.

[8] R. D. Loberg, C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley et al. “Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.” Cancer Research, vol. 67, no. 19, pp. 9417-9424, 2007.

[9] B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra et al.” A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer”. Cancer Research, vol. 68, no. 3, pp. 645-649, 2008.

[10] K. Fujita, C. M. Ewing, D. Y. Chan, L. A. Mangold, A. W. Partin, W. B. Isaacs et al. “Endoglin (CD105) as a urinary and serum marker of prostate cancer”. International Journal of Cancer, vol. 124, no. 3, pp. 664-669, 2009.

[11] K. Fujita, C. P. Pavlovich, G. J. Netto, Y. Konishi, W. B. Isaacs, S. Ali et al. “Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology”. Human Pathology, vol. 40, no.7, pp. 924-933, 2009.

[12] K. Fujita, T. Hayashi, K. Matsuzaki, W. Nakata, M. Masuda, A. Kawashima et al. “Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer”. Oncotarget.10987, 2016.

[13] J. J. Tosoian, S. Loeb, A. Kettermann, P. Landis, D. J. Elliot, J. I. Epstein et al. “Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program”. Journal of Urology, vol. 183, no.2, pp. 534-538, 2010.

[14] J. Baden, G. Green, J. Painter, K. Curtin, J. Markiewicz, J. Jones et al. “Multicenter evaluation of an investigational prostate cancer methylation assay”. Journal of Urology, vol. 182, no.3, pp. 1186-1193, 2009.

[15] N. V. Desireddi, P. L. Campbell, J. A. Stern, R. Sobkoviak, S. Chuai, S. Shahrara et al. “Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome”. Journal of Urology, vol. 179, no.5, pp. 1857-1861, 2008.

[16] G. Ghoniem, N. Faruqui, M. Elmissiry, A. Mahdy, H. Abdelwahab, M. Oommen et al. “Differential profile analysis of urinary cytokines in patients with overactive bladder”. Intenational Urogynecology Journal. 2011;22, no. 8, 953– 61. vol. 22, pp. 953-61, 2011.

[17] P. Tyagi, S. Motley, M. Kashyap, S. Pore, J Gingrich, Z. Wang et al. “Urine chemokines indicate pathogenic association of obesity with BPH/LUTS”. International Urology and Nephrology. vol. 47, no. 7, pp. 1051-8, 2015.